Stockscreener 앱 받기
0.7569
7.14%
-0.0582
시간 외 거래:
.77
0.0131
+1.73%
전일 마감가:
$0.8151
열려 있는:
$0.813
하루 거래량:
395.23K
Relative Volume:
0.84
시가총액:
$10.40M
수익:
$11.65M
순이익/손실:
$-36.56M
주가수익비율:
-0.2058
EPS:
-3.677
순현금흐름:
$-30.09M
1주 성능:
-25.06%
1개월 성능:
-33.61%
6개월 성능:
-55.48%
1년 성능:
-72.77%
1일 변동 폭
$0.75
$0.83
1주일 범위
$0.75
$1.0309
52주 변동 폭
$0.75
$3.13
Curis Inc Stock (CRIS) Company Profile
명칭
Curis Inc
전화
617-503-6500
주소
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
0.7569 | 11.20M | 11.65M | -36.56M | -30.09M | -3.677 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2023-11-17 | 개시 | Truist | Buy |
| 2022-04-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | 개시 | Raymond James | Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2020-07-29 | 개시 | Laidlaw | Buy |
| 2020-07-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2016-03-02 | 개시 | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-08-11 | 개시 | FBR Capital | Outperform |
| 2015-01-22 | 재확인 | Oppenheimer | Outperform |
| 2015-01-21 | 재확인 | ROTH Capital | Buy |
| 2014-05-09 | 재확인 | Oppenheimer | Outperform |
| 2013-10-02 | 개시 | Robert W. Baird | Outperform |
| 2013-09-30 | 개시 | Chardan Capital Markets | Buy |
| 2012-11-14 | 개시 | Stifel Nicolaus | Hold |
| 2012-01-31 | 재확인 | Brean Murray | Buy |
| 2012-01-31 | 재확인 | Summer Street Research | Buy |
| 2011-12-09 | 개시 | Oppenheimer | Outperform |
| 2011-10-06 | 개시 | Summer Street Research | Buy |
| 2011-09-22 | 개시 | MLV Capital | Buy |
| 2011-03-21 | 재확인 | Brean Murray | Buy |
| 2010-02-26 | 재확인 | Roth Capital | Buy |
| 2010-01-07 | 개시 | Roth Capital | Buy |
모두보기
Curis Inc 주식(CRIS)의 최신 뉴스
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ... By GuruFocus - Investing.com Canada
Curis Q4 2025 Earnings Call Transcript - MarketBeat
Curis targets full enrollment in PCNSL registrational study within 12–18 months while advancing CLL proof-of-concept - MSN
Curis Inc’s NHL Prioritization, PCNSL Timeline Shifts, and CLL Data Delays Clash in 2025 Q4 Earnings Call - Bitget
Curis Reports Progress on Lymphoma Study & Expands CLL Research with EmavusertibNews and Statistics - IndexBox
Curis (CRIS) Q4 2025 Financial Results Conference Call Transcript - Bitget
Curis (CRIS) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Curis Inc. Q4 2025 sees turnaround with net income - Investing.com
Curis: Fourth Quarter Earnings Overview - Bitget
Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Curis (CRIS) Q4 2025 Earnings Call Transcript - The Motley Fool
Curis Provides Fourth Quarter 2025 Business Update - Bitget
Curis (CRIS) Reports Lower Than Expected Q4 Revenue - GuruFocus
Curis Q4 & Full-Year 2025 Financial Results: $19.4M Net Income, $1.1M RevenueNews and Statistics - IndexBox
Curis: Overview of Fourth Quarter Financial Results - Bitget
Curis reports Q4 results, secures up to $80.8M financing By Investing.com - Investing.com Canada
Curis Inc Q4 revenue misses estimates - TradingView
Curis: Q4 Earnings Snapshot - marketscreener.com
Curis’s Emavusertib Trial Pause: What AML and MDS Investors Need to Know - TipRanks
Curis, Inc. 8-K SEC Filing Details: Company Information, Address, and Regulatory Compliance (March 17, 2026) - Minichart
Curis Shareholders Approve Major Equity and Charter Changes - TipRanks
Curis (NASDAQ: CRIS) ups share authorization and clears expansive 2026 incentive plan - Stock Titan
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026 - BioSpace
CRIS Earnings History & Surprises | EPS & Revenue Results | CURIS INC (NASDAQ:CRIS) - ChartMill
Aug Outlook: What are analysts price targets for Curis IncJuly 2025 Price Swings & Reliable Price Breakout Alerts - baoquankhu1.vn
Travel Stocks: Is Curis Inc stock a value trapJuly 2025 Earnings & Technical Confirmation Trade Alerts - baoquankhu1.vn
Head-To-Head Analysis: eXoZymes (NASDAQ:EXOZ) & Curis (NASDAQ:CRIS) - Defense World
Bull Run: Will Curis Inc benefit from AI trendsMarket Risk Summary & Reliable Intraday Trade Plans - baoquankhu1.vn
CRIS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Curis Inc. a speculative investmentJuly 2025 Rallies & Low Volatility Stock Recommendations - mfd.ru
Aug Chart Watch: Is Curis Inc a potential multi baggerJuly 2025 EndofMonth & Breakout Confirmation Trade Signals - baoquankhu1.vn
Can Curis Inc. stock hit analyst price targetsMarket Activity Recap & Weekly Watchlist for Hot Stocks - mfd.ru
Large share increase and PIPE-driven dilution on ballot at Curis (NASDAQ: CRIS) - Stock Titan
Armistice Capital (CRIS) reports 1.34M shares, 9.99% ownership - Stock Titan
What’s the MACD signal for Curis Inc.July 2025 Retail & Consistent Profit Trading Strategies - mfd.ru
Curis (CRIS) Moves to Offer Over 107 Million Shares of Common St - GuruFocus
Curis Provides Third Quarter 2024 Business Update - GuruFocus
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), some shareholders of the biopharmaceutical company Curis Inc plan to resell their ordinary shares in the open market in an irregular and batch-by-batch manner. - Bitget
What are Curis Inc.’s recent SEC filings showing2025 Key Lessons & Real-Time Buy Signal Notifications - mfd.ru
Is Curis Inc. (CUS0) stock positioned for secular growthLayoff News & Low Drawdown Trading Strategies - mfd.ru
How The Narrative Around Curis (CRIS) Is Shifting As Assumptions Change Not The US$14 Target - Yahoo Finance
Curis regains compliance with Nasdaq listing standards, enters monitoring period - Investing.com
Curis Regains Nasdaq Compliance, Remains Under Monitoring Period - TipRanks
Curis (CRIS) targets major share hike to unlock PIPE and new 2026 equity plan - Stock Titan
Curis Advances Clinical Pipeline with Focus on Leukemia Treatments - AD HOC NEWS
Buyout Rumor: Is Curis Inc a potential multi bagger2025 Market WrapUp & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Curis (CRIS) to Release Earnings on Wednesday - Defense World
Panic Selling: Is Curis Inc exposed to political riskQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Aug Drivers: Is Curis Inc stock a value trap2025 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn
Is Curis Inc. stock a value trapJuly 2025 Chart Watch & High Accuracy Swing Trade Signals - mfd.ru
Curis Targets BTKi-Exposed CLL With New Emavusertib Combo Trial: What Investors Should Watch - TipRanks
Curis Inc (CRIS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):